Developing a Semi-Supervised Approach Using a PU-Learning-Based Data Augmentation Strategy for Multitarget Drug Discovery
International Journal of Molecular Sciences · 28.07.2024 · 25 (15) · 8239
DOI: 10.3390/ijms25158239 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.07.2024. Verfasst von Yang Hao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou 215123, China. Hauptthemen laut MEDLINE: Drug Discovery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Science and Technology Program, SIP High-Quality Innovation Platform for Chronic Diseases.
Abstract (Originalsprache)
Multifactorial diseases demand therapeutics that can modulate multiple targets for enhanced safety and efficacy, yet the clinical approval of multitarget drugs remains rare. The integration of machine learning (ML) and deep learning (DL) in drug discovery has revolutionized virtual screening. This study investigates the synergy between ML/DL methodologies, molecular representations, and data augmentation strategies. Notably, we found that SVM can match or even surpass the performance of state-of-the-art DL methods. However, conventional data augmentation often involves a trade-off between the true positive rate and false positive rate. To address this, we introduce Negative-Augmented PU-bagging (NAPU-bagging) SVM, a novel semi-supervised learning framework. By leveraging ensemble SVM classifiers trained on resampled bags containing positive, negative, and unlabeled data, our approach is capable of managing false positive rates while maintaining high recall rates. We applied this method to the identification of multitarget-directed ligands (MTDLs), where high recall rates are critical for compiling a list of interaction candidate compounds. Case studies demonstrate that NAPU-bagging SVM can identify structurally novel MTDL hits for ALK-EGFR with favorable docking scores and binding modes, as well as pan-agonists for dopamine receptors. The NAPU-bagging SVM methodology should serve as a promising avenue to virtual screening, especially for the discovery of MTDLs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wisdom Lake Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou 215123, China.
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 7ZX, UK.
- School of Life Sciences, Fudan University, Shanghai 200092, China.
ORCID-Profile: Bo Li, Daiyun Huang, Sijin Wu, Lei Fu, Xin Liu
Förderung
- National Natural Science Foundation of China
- Jiangsu Science and Technology Program
- SIP High-Quality Innovation Platform for Chronic Diseases
- XJTLU Research Development Fund
Zitieren
APA
Hao, Y., Li, B., Huang, D., Wu, S., Wang, T., Fu, L., & Liu, X. (2024). Developing a Semi-Supervised Approach Using a PU-Learning-Based Data Augmentation Strategy for Multitarget Drug Discovery. International Journal of Molecular Sciences, 25(15), 8239. https://doi.org/10.3390/ijms25158239
Vancouver
Hao Y, Li B, Huang D, Wu S, Wang T, Fu L, et al. Developing a Semi-Supervised Approach Using a PU-Learning-Based Data Augmentation Strategy for Multitarget Drug Discovery. International Journal of Molecular Sciences. 2024;25(15):8239. doi:10.3390/ijms25158239
BibTeX
@article{Hao2024,
author = {Hao, Yang and Li, Bo and Huang, Daiyun and Wu, Sijin and Wang, Tianjun and Fu, Lei and Liu, Xin},
title = {Developing a Semi-Supervised Approach Using a PU-Learning-Based Data Augmentation Strategy for Multitarget Drug Discovery},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {15},
pages = {8239},
doi = {10.3390/ijms25158239}
}
EUVIMED